Frontiers | CD56 in the Immune System: More Than a Marker for Cytotoxicity?
Memory responses of natural killer cells. - Abstract - Europe PMC
Human NK cell receptors/markers: A tool to analyze NK cell development, subsets and function
Harnessing Natural Killer Cell-Mediated Innate Immune Responses for Cancer Treatment: Advances and Challenges
IJMS | Free Full-Text | Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy | HTML
CD antigens expression in NK cells
Frontiers | Natural Killer Cells: Development, Maturation, and Clinical Utilization
Cationic Nanoparticle-Mediated Activation of Natural Killer Cells for Effective Cancer Immunotherapy | ACS Applied Materials & Interfaces
CAR-NK cells: A promising cellular immunotherapy for cancer - eBioMedicine
A discrete subset of epigenetically primed human NK cells mediates antigen-specific immune responses | Science Immunology
Natural Killer NK Cell Marker (CD3, NCAM1, CD94, NKG2D, SLAMF6, NK-p44) Antibody Panel - Human (ab254014)
Cytokine-induced memory-like natural killer cells for cancer immunotherapy | Stem Cell Research & Therapy | Full Text
Innate or Adaptive Immunity? The Example of Natural Killer Cells | Science
Surface Markers of Natural Killer Cells - Cusabio
Natural Killer Cells and Their Role in Immunity - European Medical Journal
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy | Journal of Hematology & Oncology | Full Text
Cancers | Free Full-Text | NK Cell-Based Immunotherapy in Renal Cell Carcinoma | HTML
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy | Signal Transduction and Targeted Therapy
b.jpg "Antigen Markers on Mature Lymphocyte Subpopulations")
Antigen Markers on Mature Lymphocyte Subpopulations
Natural Killer Cell Markers: R&D Systems
Frontiers | Natural Killer Cells: Development, Maturation, and Clinical Utilization
Technology - Zelluna Immunotherapy AS
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways: Molecular Therapy - Methods & Clinical Development
